Key facts
- Sonire Therapeutics’s last known valuation is $31.7M (Nov 2022).
- It has raised $39.9M across 1 recorded rounds; the latest was Early Stage VC ($13.5M) in Mar 2026.
- Notable investors include MedTech Innovator, Mitsubishi UFJ Capital, SBI Investment, J-Startup, Nissay Capital — 27 tracked in total.
- Sonire Therapeutics has filed 1 Form D with the SEC, most recently Apr 2026 ($13.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Sonire Therapeutics
Funding rounds
1 roundsAbout Sonire Therapeutics
Developer of high-intensity focused ultrasound therapy systems designed to revolutionize medical therapy for the treatment of cancer patients. The company offers precise tissue targeting and real-time imaging capabilities, enabling healthcare professionals specializing in oncology and non-invasive surgery to deliver effective treatments with enhanced accuracy and patient comfort.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 27
- Website
- sonire-therapeutics.com/
- Ownership
- Privately Held (backing)
Sonire Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonire Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonire Therapeutics in its N-PORT filings yet. We sweep new filings monthly.